Peripheral diabetic neuropathy. Current recommendations and future prospects for its prevention and management

Drugs

Volumn 54, Issue 3, 1997, Pages 414-421

  Fedele, Domenico ^a,c   Giugliano, Dario ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Centro Antidiabetico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTIOXIDANT; GAMMA LINOLENIC ACID; GANGLIOSIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEVACECARNINE; TOLRESTAT;

DIABETES MELLITUS; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; PERIPHERAL NEUROPATHY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT;

EID: 0030858136     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00004     Document Type: Review

References (47)

1. Consensus statement: report and recommendations of the San Antonio Conference on Diabetic Neuropathy [editorial]. Diabetes 1988; 37 (7): 1000-4
2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-88, 252-63
3. Fedele D, Comi GC, Coscelii C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 1997; 20: 830-7
4. American Diabetes Association. Diabetes 1996: vital statistics. Alexandria: ADA, 1996: 1-102
5. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med 1996; 124 (1 Pt 2): 86-9
6. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab Metab Rev 1995; 11 (3): 193-225
7. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122 (8): 561-8
8. Reichard P, Nilsson BY, Rosenquisit U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9
9. Greene DA, Lattimer-Greene S, Sima AAF. Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism. Crit Rev Neurobiol 1989; 5: 143-219
10. Jamal GA. Pathogenesis of diabetic neuropathy: the role of the ω-6-essential fatty acids and their eicosanoid derivatives. Diabetic Med 1990; 7: 574-9
11. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67
12. Thomas PK. Growth factors and diabetic neuropathy. Diabetic Med 1994; 11: 732-9
13. Dyck PJ. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? Neurology 1989; 39: 111-8
14. Morley GK, Mooradian AD, Levine AS, et al. Mechanism of pain in diabetic peripheral neuropathy: effect of glucose on pain perception in humans. Am J Med 1984; 77: 79-82
15. Young RJ, Clarke BF. Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs. Diabetic Med 1985; 2: 363-6
16. Rull JA, Quibrera R, Gonzales-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (tegretol): double blind cross-over trial. Diabetologia 1969; 5: 215-8
17. Davis JL, Lewis SB, Gerich JE, et al. Peripheral diabetic neuropathy treated with amitriplyline and fluphenazine. JAMA 1977; 238: 2291-2
18. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-6
19. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; 1: 9-11
20. Stracke H, Meyer U, Schumacher HE, et al. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 11: 1550-5
21. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992; 15: 159-65
22. Levy DM, Abraham RR, Tomlinson DR. Topical capsaicin in the treatment of painful neuropathy [letter]. N Engl J Med 1991; 324: 776
23. Solders G, Tyden G, Persson A, et al. Improvement in diabetic neuropathy 4 years after successful pancreatic and renal transplantation. Diabetologia 1991; 34 Suppl. 1: S125-7
24. Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 1981; 30: 459-64
25. Fagius J, Brattberg A, Jameson S, et al. Limited benefit of treatment of diabetic polyneuropathy with an aldose-reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323-9
26. Greene DA. Effects of aldose reductase inhibitors on the progression of nerve fibre damage in diabetic neuropathy. J Diabetes Complications 1992; 6: 35-8
27. Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33: 431-7
28. Giugliano D, Marfella R, Quatraro A, et al. Tolrestat for mild diabetic neuropathy: a 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993; 118: 7-11
29. Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536-41
30. Coscelli C, Cucinotta D, Santeusanio F, et al. Safety of tolrestat in diabetic neuropathy: the Italian multicentre surveillance study. Clin Drug Invest 1995; 10: 235-41
31. Nicolucci A, Carinci F, Graepel JG, et al. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: a meta-analysis of individual patient data. Diabetes Care 1996; 19: 1091-6
32. Wyeth-Recordati Pharmaceuticals. Unpublished study, protocol no. 709A-902-1T
33. Ledeen RW, Yu K, Rapport MM, Swanki K. editors. Ganglioside structure, function and biomedical potential. Adv Exper Med Biol. Vol. 174. Plenum Press. New York, 1984
34. Abraham RR, Levy DM, Abraham RM. Changes in thermal sensation in diabetic patients after treatment with gangliosides. Diah Res Clin Pract 1988; 7: 129-35
35. Fedele D, Crepaldi G, Battistin L. Multicenter trial on gangliosides in diabetic peripheral neuropathy. Adv Exp Med Biol 1984; 174: 601-6
36. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streplozotocin-diabetic rats. Diabetologia 1992; 35: 12-8
37. Jamal GA, Carmichael H. The effect of γ-linoleic acid on human diabetic peripheral neuropathy: a double-blind placebo controlled trial. Diabetic Med 1990; 7: 319-23
38. γ-Linolenic Acid Multicenter Trial Group. Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 1993; 16: 8-15
39. Ido Y, McHowat J, Chang KC, et al. Neuronal dysfunction and metabolic imbalances in diabetic rats: prevention by acetylL-carnitine. Diabetes 1994; 43: 1469-77
40. Quatraro A, Roca P, Donzella C, et al. Acety-L-carnitine for symptomatic diabetic neuropathy [letter]. Diabetologia 1995; 38: 123
41. Sigma-Tau Pharmaceuticals. Unpublished study, protocol no. DRN 20032891/ALC-ST200
42. Kihara M, Schmelzer JD, Poduslo JF, et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-11
43. Van Dam PS. Van Asbeck BS, Erkelens DW, et al. The role of oxidative stress in neuropathy and other diabetic complications. Diab Metab Rev 1995; 11: 181-92
44. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33
45. Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Med 1996; 2: 703-7
46. Dyck PJ. Nerve growth factor and diabetic neuropathy. Lancet 1996; 348: 1044-5
47. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present and future. Diabetes 1995; 44: 1355-61